Current Status and Future Directions for Immunotherapy in Hepatocellular Carcinoma

Download this slideset from Bruno Sangro, MD, PhD, to see the latest data on immunotherapy treatment options for patients with hepatocellular carcinoma.

Bruno Sangro, MD, PhD Released: October 14, 2020

Download this slideset from Ghassan K. Abou-Alfa, MD, MBA, to see the latest data on first-line immunotherapy treatment options for patients with advanced hepatocellular carcinoma.

Ghassan K. Abou-Alfa, MD, MBA
Program Director Released: October 14, 2020

Download this slideset from Peter R. Galle, MD, PhD, to see the latest data on immunotherapy treatment options for patients with early or intermediate-stage hepatocellular carcinoma.

Peter R. Galle, MD, PhD Released: October 14, 2020

Download this short summary slideset of key takeaway points from a live presentation on the current status and future directions for immunotherapy in hepatocellular carcinoma.

Ghassan K. Abou-Alfa, MD, MBA
Program Director Peter R. Galle, MD, PhD Bruno Sangro, MD, PhD Released: October 26, 2020

Get up to date on how European experts leverage immune checkpoint inhibitor–based therapy to optimally treat patients with early-stage through metastatic hepatocellular carcinoma.

Ghassan K. Abou-Alfa, MD, MBA
Program Director Peter R. Galle, MD, PhD Bruno Sangro, MD, PhD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Released: October 26, 2020 Expired: October 25, 2021

Immunotherapy in Hepatocellular Carcinoma

IO Combinations in First-line Advanced HCC: Current Evidence and Ongoing Trials

IO Combinations Early or Intermediate-Stage HCC: Current Evidence and Ongoing Trials

Case Discussion